The U.S. Food and Drug Administration (FDA) has approved a new, personalized cell therapy that supercharges the patient’s immune system to find and kill cancer cells.

The therapy, axicabtagene ciloleucel (Yescarta ™), is the second of this new method of treatment, known as CAR (chimeric antigen receptor) T-cell immunotherapy, to receive FDA approval for blood cancer patients in the past six weeks, and the first to treat patients with lymphoma.

The Leukemia and Lymphoma Society has supported the clinical trial leading to the approval of Yescarta since 2015 through its Therapy Acceleration Program® (TAP). Through TAP, LLS partners directly with biotechnology companies, including the developer of Yescarta, Kite, a Gilead Company, to help accelerate the development of promising treatments.